trending Market Intelligence /marketintelligence/en/news-insights/trending/esxZzTx8qdQm08CzR0MGdQ2 content esgSubNav
In This List

Histogenics terminates CEO, COO, reduces staff under cost-saving restructuring

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation

Blog

Using Credit Analytics to Avoid Mispricing Insurance Premiums

Blog

Post-Webinar Q&A: Integrating Climate Risks into Credit Risk Portfolios


Histogenics terminates CEO, COO, reduces staff under cost-saving restructuring

Histogenics Corp. is terminating the positions of CEO Adam Gridley and COO Stephen Kennedy as part of a restructuring plan to reduce costs and eliminate all but one of the company's employees.

Histogenics expects to record a one-time charge of about $2.2 million in severance and related expenses. The company intends to substantially complete the restructuring by the end of the first quarter.

Histogenics' evaluation of strategic alternatives is expected to be handled by Gridley and Kennedy, who will continue to consult the company, along with up to four additional employees who the company intends to engage as consultants upon their separation from service.

Gridley will retain his statutory titles as president, treasurer and secretary of the Waltham, Mass.-based clinical-stage company and will remain a director of Histogenics but will not receive compensation for the position.